Review of the Treatment of Restless Legs Syndrome: Focus on Gabapentin Enacarbil

The FDA approved gabapentin enacarbil in 2011 as the first non-dopaminergic agent for the treatment of restless legs syndrome (RLS) symptoms. Although gabapentin enacarbil is a pro-drug of gabapentin, its pharmacokinetics differ. Absorption of gabapentin enacarbil is more predictable, and inter-pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Burke, Rachel A., Faulkner, Michele A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619699/
https://www.ncbi.nlm.nih.gov/pubmed/23650473
http://dx.doi.org/10.4137/JCNSD.S9107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619699/
https://www.ncbi.nlm.nih.gov/pubmed/23650473
http://dx.doi.org/10.4137/JCNSD.S9107

Ejemplares similares